NARCOLEPSY TYPE 2
Clinical trials for NARCOLEPSY TYPE 2 explained in plain language.
Never miss a new study
Get alerted when new NARCOLEPSY TYPE 2 trials appear
Sign up with your email to follow new studies for NARCOLEPSY TYPE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New narcolepsy drug aims to keep patients awake and strong
Symptom relief Not yet recruitingThis study tests a drug called samelisant in 240 people with narcolepsy (with or without cataplexy). The goal is to see if it reduces excessive daytime sleepiness and sudden muscle weakness episodes over 12 weeks. Participants will take the drug or a placebo and report their slee…
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE3 • Sponsor: Suven Life Sciences Limited • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New dosing options for xywav could help fight daytime sleepiness
Symptom relief Not yet recruitingThis Phase 3 study tests whether expanded dosing regimens of Xywav can safely reduce excessive daytime sleepiness in adults with narcolepsy or idiopathic hypersomnia. About 108 participants will receive either Xywav or a placebo in a randomized withdrawal design. The main goal is…
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC